Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trials of convalescent plasma for passive immunotherapy of MERS-CoV infection may be feasible, but such trials would be challenging because of the small pool of potential donors with sufficiently high antibody titers. Alternative strategies to identify convalescent plasma donors with adequate antibody titers should be explored, including the sampling of serum from patients with more severe disease and sampling at earlier points during illness.

Original publication

DOI

10.3201/eid2209.151164

Type

Journal article

Journal

Emerg Infect Dis

Publication Date

09/2016

Volume

22

Pages

1554 - 1561

Keywords

ELISA, IFA, MERS, MERS-CoV, Middle East respiratory syndrome, Middle East respiratory syndrome coronavirus, Saudi Arabia, antibody titers, convalescent phase, convalescent plasma, convalescent-phase plasma, feasibility study, humans, immunotherapy, indirect immunofluorescent antibody assay, intensive care, microneutralization, neutralizing antibodies, respiratory infections, seroreactive, viruses, Antibodies, Neutralizing, Antibodies, Viral, Coronavirus Infections, Enzyme-Linked Immunosorbent Assay, Health Personnel, Humans, Immunoglobulin G, Immunotherapy, Middle East Respiratory Syndrome Coronavirus, Neutralization Tests, Plasma, RNA, Viral, Reverse Transcriptase Polymerase Chain Reaction, Saudi Arabia